Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVL Nuvalent	$76.08 +3.3%	$78.60	$55.53 ▼ $113.51	$5.49B	1.3	538,811 shs	391,799 shs
RNA Avidity Biosciences	$46.35 +3.8%	$35.33	$21.51 ▼ $56.00	$5.96B	0.95	1.84 million shs	1.89 million shs
RYTM Rhythm Pharmaceuticals	$103.27 +1.6%	$81.14	$44.31 ▼ $104.87	$6.86B	2.38	665,837 shs	711,778 shs
TVTX Travere Therapeutics	$17.92 +0.7%	$15.98	$8.50 ▼ $25.29	$1.60B	0.74	1.65 million shs	1.91 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVL Nuvalent	+0.56%	-4.10%	-8.71%	+0.22%	-10.90%
RNA Avidity Biosciences	+0.72%	-3.06%	+33.19%	+46.04%	-0.80%
RYTM Rhythm Pharmaceuticals	+3.02%	+5.39%	+15.78%	+63.05%	+124.06%
TVTX Travere Therapeutics	-1.00%	-2.41%	+13.60%	+12.31%	+104.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NUVL Nuvalent	3.3659 of 5 stars	4.5	1.0	0.0	3.2	3.3	0.0
RNA Avidity Biosciences	3.1393 of 5 stars	4.5	2.0	0.0	3.9	0.8	0.0
RYTM Rhythm Pharmaceuticals	3.7389 of 5 stars	2.5	3.0	4.3	3.3	0.8	0.6
TVTX Travere Therapeutics	2.5733 of 5 stars	3.4	3.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NUVL Nuvalent	3.08	Buy	$118.91	56.29% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.55% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$101.57	-1.64% Downside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.21	79.77% Upside

Current Analyst Ratings Breakdown

Latest TVTX, RYTM, RNA, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/10/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $100.00
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $31.00
8/7/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $32.00
8/6/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$119.00 ➝ $120.00
8/6/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$130.00 ➝ $135.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A
RNA Avidity Biosciences	$10.90M	547.06	N/A	N/A	$9.27 per share	5.00
RYTM Rhythm Pharmaceuticals	$156.29M	43.89	N/A	N/A	($0.18) per share	-573.72
TVTX Travere Therapeutics	$233.18M	6.85	N/A	N/A	$0.37 per share	48.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	N/A
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$3.01	N/A	N/A	N/A	-117.13%	-1,831.43%	-48.33%	11/4/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-717.68%	-30.69%	10/30/2025 (Estimated)

Latest TVTX, RYTM, RNA, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.66	-$0.75	-$0.09	-$0.75	$43.72 million	$48.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NUVL Nuvalent	N/A	13.57	13.57
RNA Avidity Biosciences	N/A	9.26	9.26
RYTM Rhythm Pharmaceuticals	N/A	2.79	2.64
TVTX Travere Therapeutics	9.50	2.00	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NUVL Nuvalent	97.26%
RNA Avidity Biosciences	N/A
RYTM Rhythm Pharmaceuticals	N/A
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
NUVL Nuvalent	10.20%
RNA Avidity Biosciences	3.83%
RYTM Rhythm Pharmaceuticals	6.10%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable
RYTM Rhythm Pharmaceuticals	140	66.42 million	62.37 million	Optionable
TVTX Travere Therapeutics	460	89.14 million	85.40 million	Optionable

TVTX, RYTM, RNA, and NUVL Headlines

Recent News About These Companies

Aberdeen Group plc Raises Stock Holdings in Travere Therapeutics, Inc. $TVTX

August 22 at 4:18 AM | marketbeat.com

Nuveen LLC Makes New Investment in Travere Therapeutics, Inc. $TVTX

August 20 at 3:51 AM | marketbeat.com

Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to "Buy"

August 19 at 2:25 AM | americanbankingnews.com

Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts

August 18, 2025 | msn.com

Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to Buy

August 17, 2025 | marketbeat.com

Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Price Target at $32.21

August 15, 2025 | americanbankingnews.com

Informed Momentum Co LLC Invests $2.69 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 14, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 13, 2025 | marketbeat.com

TVTX FY2025 EPS Forecast Boosted by Cantor Fitzgerald

August 12, 2025 | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Analysts

August 12, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings

August 11, 2025 | marketbeat.com

Travere Therapeutics price target raised to $32 from $30 at Wedbush

August 8, 2025 | finance.yahoo.com

Travere Therapeutics (NASDAQ:TVTX) Given New $31.00 Price Target at Scotiabank

August 8, 2025 | marketbeat.com

Wedbush Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $32.00

August 8, 2025 | marketbeat.com

Travere Therapeutics shares rise as Q2 results top expectations

August 7, 2025 | investing.com

Travere Therapeutics Reports Strong Q2 2025 Growth

August 7, 2025 | msn.com

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6, 2025 | seekingalpha.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

August 6, 2025 | zacks.com

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Earnings Preview: Travere Therapeutics

August 5, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TVTX, RYTM, RNA, and NUVL Company Descriptions

Nuvalent NASDAQ:NUVL

$76.08 +2.43 (+3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$76.08 0.00 (0.00%)

As of 04:30 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$46.35 +1.69 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$47.00 +0.64 (+1.39%)

As of 04:35 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$103.27 +1.59 (+1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$103.25 -0.02 (-0.02%)

As of 04:39 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$17.92 +0.13 (+0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$18.15 +0.23 (+1.28%)

As of 04:33 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time